PROCEPT BioRobotics (PRCT) News Today

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) faced a strongly negative news flow on September 15, with shares decreasing as multiple law firms publicized an existing securities class-action lawsuit and urged investors to seek lead-plaintiff status by September 22, 2026.

• Negative Sentiment: Several investor-law firms, including Pomerantz, Bragar Eagel & Squire, Portnoy Law, Bernstein Liebhard, Kaplan Fox and Hagens Berman, announced reminders about the lawsuit and the approaching deadline. The volume of notices increases headline and litigation risk for PROCEPT, although these announcements largely repeat the same underlying allegations. Pomerantz investor alert
• Negative Sentiment: The complaint covers investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026. The allegations include that the company pulled forward handpiece demand through undisclosed or late-quarter bulk discounts, leaving excess inventory in the field and contributing to weaker subsequent unit sales. Levi and Korsinsky investor alert
• Negative Sentiment: Some notices specifically target purchasers in PROCEPT’s October 2024 registered offering, alleging that offering-period disclosures failed to adequately describe discount-driven handpiece ordering and inventory risks. If successful, the litigation could create legal costs, potential damages and additional scrutiny of the company’s sales practices and disclosures. Shareholder alert regarding the October 2024 offering

The announcements do not represent a new financial filing or a judgment against PROCEPT BioRobotics; they primarily repeat allegations and solicitations for investors. Nevertheless, the concentrated litigation coverage is the clearest near-term explanation for the stock’s weakness and may keep volatility elevated ahead of the September 22 deadline.